GLPwatch

A septal inhibitory circuit constrains alcohol reward and mediates liraglutide's suppressive effects on alcohol intake in mice.

Neuron · 2026

Last updated 2026-05-28

In mice, a drug called liraglutide—similar to GLP-1 medications used for diabetes and weight loss—reduced alcohol intake and the brain’s reward response to alcohol. The drug worked by acting on specific brain cells in the dorsal lateral septum, which normally become less active after alcohol consumption. When these cells were deactivated, alcohol intake increased, and liraglutide’s effects were blocked; when activated, alcohol-directed behavior decreased.

AI summary of the abstract below.

JournalNeuron, 2026
Citations0
Molecules liraglutide
Conditions studied Alcohol Use Disorder

Abstract

Alcohol use disorder (AUD) lacks effective brain-targeted treatments. Here, using mouse models, we show that glucagon-like peptide-1 receptor (GLP-1R) signaling in the dorsal lateral septum (dLS) regulates alcohol consumption and reward. Systemic administration of the GLP-1R agonist liraglutide decreased alcohol intake and ethanol-evoked dopamine release in the nucleus accumbens, requiring GLP-1R expression in the dLS. Alcohol consumption suppressed dLS neuronal activity, whereas liraglutide prevented alcohol-induced suppression of transient calcium dynamics. Inactivation of these neurons increased alcohol consumption and abolished the behavioral effects of liraglutide, whereas chemogenetic activation suppressed alcohol-directed behavior. Circuit-level analysis identified a local inhibitory projection from dLS neurons to estrogen receptor 1-expressing neurons in the ventral lateral septum (vLS neurons), and targeted manipulation of this circuit confirmed its role in regulating alcohol intake. Together, these findings delineate a septal inhibitory circuit through which GLP-1R signaling modulates alcohol-related behaviors and highlight the dLS as a therapeutic target for AUD.

Verbatim abstract via PubMed 41903537 ↗

Related research